Page 19 - GTM-4-3

Global Translational Medicine Inflammation in CVD: Mechanisms and markers

14. Sagulenko V, Thygesen SJ, Sester DP, et al. AIM2 and NLRP3 52 (stabilization of plaque using darapladib-thrombolysis
inflammasomes activate both apoptotic and pyroptotic in myocardial infarction 52) trial. J Am Heart Assoc.
death pathways via ASC. Cell Death Differ. 2013;20(9):1149- 2017;6(10):e005637.
1160. doi: 10.1161/JAHA.117.005637
doi: 10.1038/cdd.2013.37 18. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis
15. Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin and risk of atherosclerotic cardiovascular disease. N Engl J
1α: A comprehensive review on the role of IL-1α in Med. 2017;377(2):111-121.
the pathogenesis and treatment of autoimmune and doi: 10.1056/NEJMoa1701719
inflammatory diseases. Autoimmun Rev. 2021;20(2):102763.
19. Khetarpal SA, Qamar A, Bick AG, et al. Clonal hematopoiesis
doi: 10.1016/j.autrev.2021.102763 of indeterminate potential reshapes age-related CVD: JACC
16. Ridker PM, Rane M. Interleukin-6 signaling and anti- review topic of the week. J Am Coll Cardiol. 2019;74(4):578-
interleukin-6 therapeutics in cardiovascular disease. Circ 586.
Res. 2021;128(11):1728-1746. doi: 10.1016/j.jacc.2019.05.045
doi: 10.1161/CIRCRESAHA.121.319077 20. Tall AR, Fuster JJ. Clonal hematopoiesis in cardiovascular
disease and therapeutic implications. Nat Cardiovasc Res.
17. Fanola CL, Morrow DA, Cannon CP, et al. Interleukin-6
and the risk of adverse outcomes in patients after an acute 2022;1(2):116-124.
coronary syndrome: Observations from the SOLID-TIMI doi: 10.1038/s44161-021-00015-3

Volume 4 Issue 3 (2025) 11 doi: 10.36922/GTM025100023